Longeveron Inc.
(LGVN)
undefined
undefined%
At close: undefined
1.90
3.37%
After-hours Dec 13, 2024, 07:54 PM EST
Company Description
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions.
The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors.
It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome.
The company was incorporated in 2014 and is based in Miami, Florida.
Longeveron Inc.
| Country | United States |
| IPO Date | Feb 12, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Mohamed Wa'el Ahmed Hashad M.B.A. |
Contact Details
Address: 1951 NW 7th Avenue Miami, Florida United States | |
| Website | https://www.longeveron.com |
Stock Details
| Ticker Symbol | LGVN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001721484 |
| CUSIP Number | 54303L104 |
| ISIN Number | US54303L1044 |
| Employer ID | 47-2174146 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mohamed Wa'el Ahmed Hashad M.B.A. | Chief Executive Officer & Director |
| Lisa A. Locklear M.B.A. | Chief Financial Officer & Treasurer |
| Brian G Rash Ph.D. | Vice President of Research & Discovery |
| Dr. Dan Gincel Ph.D. | Senior Vice President of Strategic Collaborations & Scientific Affairs |
| Dr. Joshua Michael Hare FACC, M.D. | Co-Founder, Chief Science Officer & Chairman |
| Dr. Nataliya Agafonova M.D. | Chief Medical Officer |
| Elly Ryu | Vice President & Corporate Controller |
| Lisa McClain-Moss | Vice President of Manufacturing |
| Michael Mannarino | Vice President & Corporate Controller |
| Paul T. Lehr J.D. | International Executive Director, General Counsel & Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 04, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Oct 03, 2024 | 4 | Filing |
| Oct 03, 2024 | 4 | Filing |
| Oct 03, 2024 | 4 | Filing |
| Oct 03, 2024 | 4 | Filing |
| Aug 19, 2024 | 4 | Filing |
| Aug 19, 2024 | 4 | Filing |